Login to Your Account



Clinic Roundup


Friday, July 12, 2013
• Psivida Corp., of Watertown, Mass., said interim data from a three-year, investigator-sponsored Phase I/II study of its injectable micro-insert in patients with posterior uveitis showed none of the treated eyes had a recurrence of uveitis through the first 12 months of enrollment, and inflammation was reduced in all treated eyes.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription